A trio of high-octane income stocks -- sporting an average yield of 6.65% -- can fatten investors' pocketbooks in 2025 (and ...

Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...

Pfizer announced Jeffrey Legos, PhD, MBA as its new chief oncology officer. Bluejay Therapeutics announced Mary Cromwell, PhD, has joined its leadership team as SVP and head of technical operations.

The Food and Drug Administration expanded its approval of one of Pfizer's drugs, Adcetris, allowing it to be used as a treatment for certain types of lymphoma.

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), in ...

New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with patients.

Pam Bondi’s office had the opportunity to hold Trump University accountable for its fraudulent practices, which scammed ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Certain hormonal contraceptives are associated with a higher stroke and heart attack risk, finds a large study from Denmark in The BMJ today that draws on prescription records to give more precise ...